Table 1.
Patient’s characteristics.
| Variables | IT methotrexate n (%) |
HD-methotrexate n (%) |
No prophylaxis n (%) |
p value |
|---|---|---|---|---|
| Number (n) | 253 (43%) | 42 (7%) | 290 (50%) | |
| Median age (range) | 64 (21–86) | 63 (27–81) | 72 (24–91) | <0.001 |
| Male | 142 (56) | 24 (57) | 135 (47) | 0.07 |
| ECOG | ||||
| 0–1 | 160 (63) | 27 (64) | 142 (49) | 0.002 |
| ≥2 | 93 (37) | 15 (38) | 148 (51) | |
| Stage | ||||
| I–II | 30 (12) | 4 (10) | 30 (10) | 0.81 |
| III–IV | 223 (88) | 38 (90) | 260 (90) | |
| Serum LDH | ||||
| Above normal | 198 (78) | 28 (67) | 207 (71) | 0.14 |
| Missing | 5 (2) | 0 | 17 (6) | |
| CNS-IPI riska | ||||
| 0 | 10 (4) | 3 (7) | 12 (4) | |
| 1 | 16 (6) | 2 (5) | 18 (6) | |
| 2 | 28 (11) | 4 (10) | 17 (6) | |
| 3 | 41 (16) | 4 (9) | 31 (11) | |
| 4 | 107 (43) | 16 (38) | 157 (54) | |
| 5 | 41 (16) | 12 (29) | 49 (17) | |
| 6 | 10 (4) | 1 (2) | 6 (2) | |
| CNS-IPI risk groupsa | ||||
| Low 0–1 | 26 (10) | 5 (12) | 30 (10) | 0.009 |
| Intermediate 2–3 | 69 (27) | 8 (19) | 48 (17) | |
| High 4–6 | 158 (63) | 29 (69) | 212 (73) | |
| High risk site | ||||
| Testis | 39 (15) | 8 (19) | 4 (1) | |
| Breast | 15 (6) | 5 (12) | 27 (9) | |
| Kidney/adrenal glands | 50 (20) | 12 (29) | 44 (15) | |
| Bone marrow | 63 (25) | 6 (14) | 49 (17) | |
| Extranodal sites | ||||
| >2 sites | 87 (36) | 14 (35) | 57 (20) | <0.001 |
| Double-hit | 18 (7) | 5 (12) | 11 (4) | 0.05 |
| Treatment | ||||
| R-CHOP | 143 (57) | 32 (76) | 220 (76) | <0.001 |
| R-EPOCH | 43 (17) | 7 (17) | 40 (14) | |
| R-CHOP/RICE | 67 (26) | 3 (7) | 30 (10) | |
| Cell of origin | ||||
| Germinal center | 104 (41) | 14 (33) | 116 (40) | 0.15 |
| Non-germinal center | 104 (41) | 23 (55) | 102 (35) | |
| Missing | 45 (18) | 5 (12) | 72 (25) | |
IT intrathecal, MTX methotrexate, HD high-dose, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, CNS-IPI central nervous system international prognostic index, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, R-EPOCH rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone, RICE rituximab, ifosfamide, carboplatin, etoposide.
aIncludes patients who were missing baseline LDH but were grouped regardless of its value.